MitoRx Therapeutics operates as a platform biotech focused on translating mitochondrial biology into novel therapeutics for obesity and broader metabolic disorders. Its lead candidates are innovative small-molecule metabolic modulators designed to induce weight loss without compromising muscle integrity, a key differentiator in the crowded obesity-drug landscape. The company is currently at the preclinical stage and is building a pipeline around these modulators. With its recent pre-seed capital raise of roughly $7.3 million, MitoRx will accelerate preclinical validation studies, prepare for future regulatory submissions, and expand both its scientific team and laboratory infrastructure. Management plans to deploy the funds toward advancing its lead programs through early development milestones. Although still pre-revenue, the influx of capital signifies investor confidence in the company’s scientific approach and commercial potential. MitoRx’s near-term objectives include scaling its research footprint and progressing toward clinical readiness. Over the longer term, it aims to deliver differentiated treatments that improve metabolic health and preserve muscle mass in millions of patients.

Total raised

$12M

Funding rounds

2

Latest round

Series A

Latest activity

Dec 2025